Jay Walls, MD
Hematology & Oncology · Greenville, SCNPI 1821093956
Payments from drug & device makers
Across 96 payments — averaging $37.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$455
- Incyte Corporation$354
- Janssen Scientific Affairs, LLC$329
- AstraZeneca$326
- E.r. Squibb & Sons, L.L.C.$299
- Gilead$264
- plus $2K from 23 others
What the payments were for
- Food & beverage$3,31792%
- Education$2888%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 9 | $455 |
| Incyte Corporation | 7 | $354 |
| Janssen Scientific Affairs, LLC | 3 | $329 |
| AstraZeneca(2 entities) | 8 | $326 |
| E.r. Squibb & Sons, L.L.C. | 7 | $299 |
| Gilead(2 entities) | 9 | $264 |
| Novartis | 9 | $230 |
| Seagen Inc. | 3 | $196 |
| Epizyme, Inc. | 1 | $121 |
| Lilly USA, LLC | 5 | $103 |
| Bayer | 4 | $103 |
| Bristol Myers Squibb | 3 | $88 |
| G1 Therapeutics, Inc. | 1 | $84 |
| Amgen | 4 | $74 |
| Karyopharm Therapeutics Inc. | 1 | $71 |
| Blueprint Medicines Corporation | 1 | $70 |
| Pfizer | 3 | $69 |
| Daiichi Sankyo Inc. | 2 | $52 |
| Merck | 2 | $49 |
| Eisai Inc. | 2 | $42 |
| Pharmaessentia USA Corporation | 2 | $39 |
| Array Biopharma Inc | 2 | $38 |
| Pharmacosmos Therapeutics Inc. | 2 | $31 |
| CSL Behring | 1 | $25 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Stemline Therapeutics Inc. | 1 | $19 |
| Foundation Medicine, Inc. | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Shield Therapeutics Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,605 in reported general payments places this provider in the 35th percentile of 166 hematology & oncology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 32 | $552,720 |
| RevlimidLenalidomide | 24 | $398,178 |
| CalquenceAcalabrutinib Maleate | 23 | $340,218 |
| Lenalidomide | 22 | $330,703 |
| XtandiEnzalutamide | 23 | $301,956 |
| VenclextaVenetoclax | 17 | $245,410 |
| XareltoRivaroxaban | 187 | $170,326 |
| EliquisApixaban | 226 | $166,695 |
| NinlaroIxazomib Citrate | 12 | $137,691 |
| Imatinib Mesylate | 31 | $122,946 |
| Enoxaparin Sodium | 50 | $18,174 |
| Hydroxyurea | 75 | $2,936 |
| Anagrelide Hcl | 16 | $2,219 |
| Oxycodone Hcl | 45 | $1,461 |
| Potassium Chloride | 60 | $1,293 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $354 | $552,72032 claims |
| Bristol Myers SquibbRevlimid | $88 | $398,17824 claims |
| AstraZenecaCalquence | $326 | $340,21823 claims |
| Johnson & JohnsonXarelto | $455 | $170,326187 claims |
| PfizerEliquis | $69 | $166,695226 claims |
| Lilly USA, LLCOlanzapine | $103 | $6311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 166 hematology & oncology providers in South Carolina.
Other hematology & oncology in Greenville
- Stephen DyarGreenville$4.5M
- Suzanne FanningGreenville$3.9M
- William EdenfieldGreenville$1.7M
- Bhumika PatelGreenville$1.5M
- Elizabeth CullGreenville$1.2M
- Xuezhong YangGreenville$871K
- Fahd QuddusGreenville$471K
- Britt BolemonGreenville$450K
- Saeeda ChowdhuryGreenville$239K
- William GluckGreenville$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.